蓝莓视频

Artificial intelligence has made protein design lightning fast, creating digital blueprints for cures to some of the most life-limiting ailments. While this means we now have thousands of new potential therapeutics, for these cures to be realized the designs need to be synthesized and validated in a laboratory environment, which can take a considerable amount of time.

Liberum Bio, part of the University of 蓝莓视频鈥檚 Velocity incubator, has raised a $1.8 million seed round to further develop its proprietary technology that is solving this problem by accelerating the synthesis and testing of unrealized life-saving therapeutics.听

鈥淥ur mission is to liberate life-saving solutions from their digital purgatory,鈥� said Aidan Tinafar, co-founder and CEO of Liberum Bio. 鈥淚f you can reduce the time and cost to test those potential lifesaving therapeutics you can save more lives faster and that鈥檚 what gets us excited every day.鈥澨�

Image L-R: Co-founders Aidan Tinafar, CEO, and Alexander Klenov, chief technology officer

Tinafar said Liberum customers鈥� protein design capabilities are outstripping their production capacity and that鈥檚 why they come to Liberum Bio.听

鈥淲e offer protein synthesis as a service on the cloud, so companies bring us their digital sequences and in as little as two weeks they receive their purified proteins,鈥� he added.听

Building on technology invented in the 1950s鈥�, the company鈥檚 cell-free technology, consisting of proprietary cartridges, highly engineered source strains and reaction mixtures, produces proteins at high yields outside of living cells, at the fraction of the usual cost and time.听

鈥淲e see ourselves not simply as a cell-free biotech company, but rather a protein synthesis powerhouse,鈥� Tinafar said. 鈥淥ur cell-free system now outperforms state-of-the-art cell-based platforms.鈥澨�

Already having shipped to more than 45 labs around the world with multiple repeat purchases, Liberum Bio plans to increase its production capacity, expand its team and increase the repertoire of available proteins for their customers.

鈥淥ur technology has the potential to completely replace traditional small-scale protein production in the laboratory,鈥� said Alexander Klenov, Liberum Bio co-founder and chief technology officer. 鈥淭he artificial intelligence that is running these companies鈥� pipelines is hungry for data and we are exponentially speeding up the process to get physical proteins made and data fed back into their algorithms.鈥�

Liberum Bio鈥檚 technology is not specific to solving the backlog of protein design in the pharmaceutical industry. Protein synthesis is used to produce enzymes that will clean the environment and materials that go into everyday consumable products.

Since joining Velocity in 2021 and gaining access to the incubator鈥檚 resources, labs and networks, Liberum Bio has filed the necessary patents and made advances key to getting the company鈥檚 groundbreaking technology into the hands of consumers.

Velocity health companies are funded in part by the Government of Canada through the Federal Economic Development Agency for Southern Ontario (FedDev Ontario).